-       Report 
- December 2023
-  265 Pages 
- Global 
   From       €3220EUR$3,600USD£2,832GBP 
            -       Report 
- January 2024
-  150 Pages 
- Global 
   From       €3444EUR$3,850USD£3,029GBP 
      €4338EUR$4,850USD£3,816GBP 
          -       Report 
- June 2025
-  250 Pages 
- India 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Saudi Arabia 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Mexico 
   From       €2495EUR$2,789USD£2,194GBP 
           -       Report 
- June 2025
-  250 Pages 
- Vietnam 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Brazil 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Japan 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- August 2024
-  200 Pages 
- Global 
   From       €3461EUR$3,869USD£3,044GBP 
          -       Report 
- December 2023
-  76 Pages 
- Global 
   From       €890EUR$995USD£783GBP 
          -       Report 
- November 2023
-  29 Pages 
- United States 
        €2236EUR$2,500USD£1,967GBP 
          -       Report 
- September 2023
-  114 Pages 
- Global 
   From       €2639EUR$2,950USD£2,321GBP 
          -       Report 
- September 2023
-  194 Pages 
- Global 
   From       €4428EUR$4,950USD£3,895GBP 
          -       Report 
- February 2023
- Global 
        €4990EUR$5,976USD£4,543GBP 
          -       Report 
- March 2021
-  137 Pages 
- Global 
   From       €4383EUR$4,900USD£3,855GBP 
          -       Report 
- January 2021
-  109 Pages 
- Global 
        €3990EUR$4,779USD£3,633GBP 
          -       Report 
- November 2024
-  78 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- January 2024
-  101 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- December 2023
-  102 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- November 2024
-  90 Pages 
- Australia 
   From       €1663EUR$1,859USD£1,463GBP 
       
      The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including    influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less   Read more